Delhi High Court Orders Review Of Indian Decision Against Ranbaxy Drug Price
This article was originally published in PharmAsia News
Executive Summary
India's Delhi High Court has ordered the government to reconsider a decision fixing the price of Ranbaxy's antibiotic Roscillin (ampicillin sodium). The National Pharmaceutical Pricing Authority had declined to review its decision, saying Ranbaxy must first bring its price for the drug into line, and then file for a review. The court ordered the Ministry of Chemicals and Fertilizers to consider the Ranbaxy request within four weeks. The ultimate decision is expected to have the force of a judicial ruling. (Click here for more